莫西沙星与左氧氟沙星治疗呼吸道感染的Meta分析

目的比较莫西沙星与左氧氟沙星在治疗呼吸道感染的有效性和安全性。方法应用RevMan5软件对国内1998—2008年发表的运用莫西沙星治疗呼吸道感染的随机对照试验进行meta分析,左氧氟沙星为对照组,结果指标包括临床总有效率、细菌清除率、不良反应发生率。结果检索到18个试验,包括1392例患者。莫西沙星总有效率优于对照组RR2.24,95%CI（1.64,3.07）;P〈0.00001];细菌清除率优于对照组RR2.35,95%CI（1.58,3.49）;P〈0.0001];不良反应发生率可能少于对照组。结论现有的证据表明,莫西沙星在治疗呼吸道感染的疗效优于左氧氟沙星。不良反应可能少于左氧氟沙星或两者无差异。

Meta-analysis on the Moxifloxacin and Levofloxacin in the Treatment of Respiratory Tract Infection

OBJECTIVE To compare the effectuality and safety of the moxifloxacin and levofloxacin in the treatment of respiratory tract infection. METHODS Using meta-analysis to evaluate the effectuality and safety of the moxifloxacin from the randomized controlled trai1s(RCTs) published from 1998 to 2008 in Chinese journals with RevMan 5. The control group were given levofloxacin, the outcome we compared included: total efficacy rata, bacterial eradication rates, adverse effect rates. RESULTS 18 RCTs and 1 392 patients which were included meta-analysis indicated that the total effective rate of moxifloxacin is superior to controlRR 2.24, 95% CI(1.64, 3.07); P<0.000 01]; the bacterial eradication rates of moxifloxacin is superior to controlRR 2.35, 95% CI(1.58, 3.49); P<0.0001]; the adverse effect rates of moxifloxacin is probablely smaller than control. CONCLUSION The effectuality of the moxifloxacin in the treatment of respiratory tract infection is better than levofloxacin. The adverse effect rates of moxifloxacin is probablely smaller than control, or no difference between the two groups.